Back to results
US 11,083,800 B2Granted
AAV virions with decreased immunoreactivity and uses therefor
AssigneeGenzyme Corporation
InventorsAlejandra E. Arbetman, Peter C. Colosi, Michael A. Lochrie, Richard T. Surosky
Life of this patent
Estimating the term…
Abstract
Methods of making and using recombinant AAV virions with decreased immunoreactivity are described. The recombinant AAV virions include mutated capsid proteins or are derived from non-primate mammalian AAV serotypes and isolates that display decreased immunoreactivity relative to AAV-2.
Claims15
A mutated adeno-associated virus serotype 2 (AAV-2) capsid protein comprising a substitution of one or more of the amino acids occurring at a position corresponding to a position of the full-length AAV-2 VP2 capsid,
- wherein the one or more amino acids comprise amino acid 449 substituted with a lysine or an alanine, and
- wherein the mutated AAV-2 capsid protein displays an increase in resistance to neutralization by one or more human IgGs as compared to the wild-type AAV-2 capsid protein.
Dependencies are inferred from the claim text.